Analysis of Pharmacy Cardiac Optimization Clinic for Patients with New Onset Atrial Fibrillation Detected via Cardiac Implantable Electronic Device Clinic

被引:0
作者
Schellhase, Ellen [1 ]
Stanko, Madeline [1 ]
Kinstler, Natalie [1 ]
Miller, Monica L. [1 ]
Antoniou, Sotiris [2 ]
Fhadil, Sadeer [2 ]
Patel, Mital [2 ]
Wright, Paul [2 ]
机构
[1] Purdue Univ Coll Pharm, W Lafayette, IN 47907 USA
[2] St Bartholomews Hosp, London EC1A 7BE, England
关键词
anticoagulation; atrial fibrillation; cardiac implantable electronic devices; cardiac pharmacists; medication optimization; direct oral anticoagulants; non-vitamin k oral anticoagulants; cardiovascular optimization; STROKE; ANTICOAGULATION; THERAPY; ORBIT; RISK;
D O I
10.3390/pharmacy11020048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For patients with cardiac implantable electronic devices (CIEDs), arrythmias such as atrial fibrillation (AF) can be detected and actions taken to rapidly assess and initiate treatment where appropriate. Actions include timely initiation of anticoagulation, review of blood pressure, and optimization of cholesterol/lipids to prevent unfavorable outcomes, such as stroke and other cardiovascular complications. Delays to initiating anticoagulation can have devastating consequences. We sought to implement a virtual clinic, where a pharmacist reviews patient referrals from a CIED clinic after detecting AF from the CIED. Anticoagulation choice is determined by patient-specific factors, and a shared patient-provider decision to start oral anticoagulation is made. In addition, blood pressure readings and medications are assessed with lipid-lowering therapies for optimization. A total of 315 patients have been admitted through this clinic and anticoagulated over a two-year span; in addition, 322 successful interventions were made for optimization of cardiac therapy. Rapid initiation of anticoagulation within five days of referral was likely to have reduced unfavorable outcomes, such as stroke and other cardiovascular optimizations, leading to improved patient outcomes.
引用
收藏
页数:7
相关论文
共 28 条
[21]   Assessing bleeding risk in patients taking anticoagulants [J].
Shoeb, Marwa ;
Fang, Margaret C. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 35 (03) :312-319
[22]  
Till L Traywick, 2003, J Manag Care Pharm, V9, P269
[23]  
University of Nottingham, 2018, EMIS WELC QRISK 3 20
[24]   Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention [J].
Virdee, Mandeep S. ;
Stewart, Derek .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) :173-180
[25]   Improving blood pressure control in a pharmacist-managed hypertension clinic [J].
Vivian, EM .
PHARMACOTHERAPY, 2002, 22 (12) :1533-1540
[26]   Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation [J].
Yao, Xiaoxi ;
Gersh, Bernard J. ;
Sangaralingham, Lindsey R. ;
Kent, David M. ;
Shah, Nilay D. ;
Abraham, Neena S. ;
Noseworthy, Peter A. .
AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (09) :1549-1556
[27]   Remote monitoring of cardiac implantable electronic devices (CIED) [J].
Zeitler, Emily P. ;
Piccini, Jonathan P. .
TRENDS IN CARDIOVASCULAR MEDICINE, 2016, 26 (06) :568-577
[28]   Cardiac device implantation in the United States from 1997 through 2004: A population-based analysis [J].
Zhon, Chunliu ;
Boine, Williom B. ;
Sedrokyan, Artyom ;
Steiner, Cloudio .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (Suppl 1) :13-19